Artiva Biotherapeutics Statistics
Total Valuation
ARTV has a market cap or net worth of $467.42 million. The enterprise value is $390.90 million.
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ARTV has 48.59 million shares outstanding. The number of shares has increased by 43.09% in one year.
| Current Share Class | 48.59M |
| Shares Outstanding | 48.59M |
| Shares Change (YoY) | +43.09% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 4.45% |
| Owned by Institutions (%) | 14.32% |
| Float | 19.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.71 |
| P/TBV Ratio | 5.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.16, with a Debt / Equity ratio of 0.12.
| Current Ratio | 8.16 |
| Quick Ratio | 8.03 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.86% and return on invested capital (ROIC) is -40.97%.
| Return on Equity (ROE) | -67.86% |
| Return on Assets (ROA) | -38.72% |
| Return on Invested Capital (ROIC) | -40.97% |
| Return on Capital Employed (ROCE) | -96.84% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$821,415 |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +501.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +501.25% |
| 50-Day Moving Average | 9.49 |
| 200-Day Moving Average | 5.65 |
| Relative Strength Index (RSI) | 56.45 |
| Average Volume (20 Days) | 725,084 |
Short Selling Information
The latest short interest is 1.08 million, so 2.22% of the outstanding shares have been sold short.
| Short Interest | 1.08M |
| Short Previous Month | 1.03M |
| Short % of Shares Out | 2.22% |
| Short % of Float | 5.42% |
| Short Ratio (days to cover) | 1.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -92.07M |
| Pretax Income | -87.07M |
| Net Income | -87.07M |
| EBITDA | -89.43M |
| EBIT | -92.07M |
| Earnings Per Share (EPS) | -$3.55 |
Full Income StatementBalance Sheet
The company has $86.78 million in cash and $10.26 million in debt, giving a net cash position of $76.52 million or $1.57 per share.
| Cash & Cash Equivalents | 86.78M |
| Total Debt | 10.26M |
| Net Cash | 76.52M |
| Net Cash Per Share | $1.57 |
| Equity (Book Value) | 87.85M |
| Book Value Per Share | 3.55 |
| Working Capital | 77.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.86 million and capital expenditures -$2.32 million, giving a free cash flow of -$80.18 million.
| Operating Cash Flow | -77.86M |
| Capital Expenditures | -2.32M |
| Depreciation & Amortization | 2.64M |
| Net Borrowing | -132,000 |
| Free Cash Flow | -80.18M |
| FCF Per Share | -$1.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |